Goffin, J. R. http://orcid.org/0000-0003-1696-8342
Nicholas, G.
Mates, M.
Tu, D.
Chen, E.
Laurie, S. A.
Juergens, R.
Robinson, A.
Goss, G.
Reaume, M.
Sun, S.
Christink, K.
Maize, C.
MacFarlan, S.
Sun, X.
Ritter, H.
Seymour, L.
Bradbury, P. A.
Funding for this research was provided by:
Canadian Cancer Society Research Institute (grant numbers 021039 and 704970)
Article History
Received: 2 August 2018
Accepted: 8 October 2018
First Online: 13 October 2018
Compliance with ethical standards
:
: Dr. Seymour received funding for the Canadian Cancer Trials Group from AstraZeneca to support this trial. Dr. Goffin has received honorarium from Amgen, Boehringer Ingelheim, and Bristol-Myers Squibb and conference travel support from AstraZeneca. Dr. Juergens has consulted for and has received grant funding from AstraZeneca. All other authors had no conflicts to report.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The study was approved by the research ethics boards of the participating institutions.
: Informed consent was obtained from all individual participants included in the study.